West Pharmaceutical Services Reports Strong Q3 2026 Results Driven by GLP-1 Demand
West Pharmaceutical Services (WST) delivered robust third-quarter 2026 financial results, characterized by significant organic growth and margin expansion. Net sales reached $874.5 million, representing an 11.9% organic increase, while adjusted diluted EPS rose 35.7% to $2.66. Growth was primarily fueled by high-value product (HVP) components, which saw a 20.3% organic increase and now account for over half of the company's total revenue. A major catalyst for performance was the GLP-1 category, which achieved organic growth exceeding 30%. Additionally, the biologics market grew by 23.2%, reflecting high demand for injectable containment solutions. Despite a decline in the West Vantage segment due to the roll-off of a legacy continuous glucose monitoring program, the company raised its full-year 2026 net sales guidance and maintained strong momentum through price realization and product mix optimization.
Tickers: $WST
Topics: adjusted eps biologics market financial guidance GLP-1 demand net sales growth organic growth